Proteolysis of α-synuclein fibrils in the lysosomal pathway limits induction of inclusion pathology

Journal of Neurochemistry

Volumn 140, Issue 4, 2017, Pages 662-678

  Sacino, Amanda N ^a   Brooks, Mieu M ^a   Chakrabarty, Paramita ^a   Saha, Kaustuv ^a   Khoshbouei, Habibeh ^a   Golde, Todd E ^a   Giasson, Benoit I ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

degradation; endocytosis; inclusions; lysosome; Parkinson's disease; synuclein

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID;

ANIMAL CELL; ARTICLE; CELL FUNCTION; CELL MEMBRANE; CONTROLLED STUDY; DIFFUSE LEWY BODY DISEASE; DISEASE COURSE; DISEASE TRANSMISSION; ENDOSOME; GLIA CELL; INTERNALIZATION; LYSOSOME; MEMBRANE BINDING; NERVE CELL; NEUROPHYSIOLOGY; NONHUMAN; PATHOGENESIS; PROTEIN AGGREGATION; PROTEIN DEFECT; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; ANIMAL; C3H MOUSE; CELL CULTURE; CELL INCLUSION; CHO CELL LINE; CRICETULUS; HAMSTER; HUMAN; KNOCKOUT MOUSE; METABOLISM; MOUSE; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ALPHA-SYNUCLEIN; AMYLOID; ANIMALS; CELLS, CULTURED; CHO CELLS; CRICETINAE; CRICETULUS; HUMANS; INCLUSION BODIES; LYSOSOMES; MICE; MICE, INBRED C3H; MICE, KNOCKOUT; PROTEOLYSIS; SIGNAL TRANSDUCTION;

EID: 84982273292     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.13743     Document Type: Article

References (72)

1. Abeliovich A., Schmitz Y., Farinas I. et al. (2000) Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25, 239–252.
2. Ahn K. J., Paik S. R., Chung K. C. and Kim J. (2006) Amino acid sequence motifs and mechanistic features of the membrane translocation of alpha-synuclein. J. Neurochem. 97, 265–279.
3. Anderson J. P., Walker D. E., Goldstein J. M. et al. (2006) Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem. 281, 29739–29752.
4. Auluck P. K., Caraveo G. and Lindquist S. (2010) Alpha-synuclein: membrane interactions and toxicity in Parkinson's disease. Annu. Rev. Cell Dev. Biol. 26, 211–233.
5. Betemps D., Verchere J., Brot S., Morignat E., Bousset L., Gaillard D., Lakhdar L., Melki R. and Baron T. (2014) Alpha-synuclein spreading in M83 mice brain revealed by detection of pathological alpha-synuclein by enhanced ELISA. Acta Neuropathol. Commun. 2, 29.
6. Bowman E. J., Siebers A. and Altendorf K. (1988) Bafilomycins: a class of inhibitors of membrane ATPases from microorganisms, animal cells, and plant cells. Proc. Natl Acad. Sci. USA 85, 7972–7976.
7. Braak H., Bohl J. R., Muller C. M., Rub U., de Vos R. A. and Del T. K. (2006a) Stanley Fahn Lecture 2005: the staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered. Mov. Disord. 21, 2042–2051.
8. Braak H., de Vos R. A., Bohl J. and Del T. K. (2006b) Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci. Lett. 396, 67–72.
9. Brundin P., Li J. Y., Holton J. L., Lindvall O. and Revesz T. (2008) Research in motion: the enigma of Parkinson's disease pathology spread. Nat. Rev. Neurosci. 9, 741–745.
10. Cuervo A. M., Stefanis L., Fredenburg R., Lansbury P. T. and Sulzer D. (2004) Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 305, 1292–1295.
11. Damme M., Suntio T., Saftig P. and Eskelinen E. L. (2015) Autophagy in neuronal cells: general principles and physiological and pathological functions. Acta Neuropathol. 129, 337–362.
12. Danzer K. M., Kranich L. R., Ruf W. P., Cagsal-Getkin O., Winslow A. R., Zhu L., Vanderburg C. R. and McLean P. J. (2012) Exosomal cell-to-cell transmission of alpha synuclein oligomers. Mol. Neurodegener. 7, 42.
13. Dehay B., Martinez-Vicente M., Caldwell G. A., Caldwell K. A., Yue Z., Cookson M. R., Klein C., Vila M. and Bezard E. (2013) Lysosomal impairment in Parkinson's disease. Mov. Disord. 28, 725–732.
14. Desplats P., Lee H. J., Bae E. J., Patrick C., Rockenstein E., Crews L., Spencer B., Masliah E. and Lee S. J. (2009) Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc. Natl Acad. Sci. USA 106, 13010–13015.
15. Doherty G. J. and McMahon H. T. (2009) Mechanisms of endocytosis. Annu. Rev. Biochem. 78, 857–902.
16. Duda J. E., Giasson B. I., Mabon M. E., Lee V. M.-Y. and Trojanoswki J. Q. (2002) Novel antibodies to oxidized a-synuclein reveal abundant neuritic pathology in Lewy body disease. Ann. Neurol. 52, 205–210.
17. Emmanouilidou E., Melachroinou K., Roumeliotis T., Garbis S. D., Ntzouni M., Margaritis L. H., Stefanis L. and Vekrellis K. (2010) Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J. Neurosci. 30, 6838–6851.
18. Fujiwara H., Hasegawa M., Dohmae N., Kawashima A., Masliah E., Goldberg M. S., Shen J., Takio K. and Iwatsubo T. (2002) α-synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 4, 160–164.
19. Giasson B. I., Uryu K., Trojanowski J. Q. and Lee V. M.-Y. (1999) Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro. J. Biol. Chem. 274, 7619–7622.
20. Giasson B. I., Jakes R., Goedert M., Duda J. E., Leight S., Trojanowski J. Q. and Lee V. M.-Y. (2000) A panel of epitope-specific antibodies detects protein domains distributed throughout human alpha-synuclein in Lewy bodies of Parkinson's disease. J. Neurosci. Res. 59, 528–533.
21. Giasson B. I., Murray I. V., Trojanowski J. Q. and Lee V. M.-Y. (2001) A hydrophobic stretch of 12 amino acid residues in the middle of alpha- synuclein is essential for filament assembly. J. Biol. Chem. 276, 2380–2386.
22. Goedert M. (2001) Alpha-synuclein and neurodegenerative diseases. Nat. Rev. Neurosci. 2, 492–501.
23. Goedert M., Spillantini M. G., Del T. K. and Braak H. (2013) 100 years of Lewy pathology. Nat. Rev. Neurol. 9, 13–24.
24. Golde T. E., Borchelt D. R., Giasson B. I. and Lewis J. (2013) Thinking laterally about neurodegenerative proteinopathies. J. Clin. Invest. 123, 1847–1855.
25. Gousset K., Schiff E., Langevin C. et al. (2009) Prions hijack tunnelling nanotubes for intercellular spread. Nat. Cell Biol. 11, 328–336.
26. Greenbaum E. A., Graves C. L., Mishizen-Eberz A. J., Lupoli M. A., Lynch D. R., Englander S. W., Axelsen P. H. and Giasson B. I. (2005) The E46K mutation in alpha -synuclein increases amyloid fibril formation. J. Biol. Chem. 280, 7800–7807.
27. Holmes B. B., DeVos S. L., Kfoury N. et al. (2013) Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proc. Natl Acad. Sci. USA 110, E3138–E3147.
28. Kordower J. H., Chu Y., Hauser R. A., Freeman T. B. and Olanow C. W. (2008) Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat. Med. 14, 504–506.
29. Kordower J. H., Dodiya H. B., Kordower A. M., Terpstra B., Paumier K., Madhavan L., Sortwell C., Steece-Collier K. and Collier T. J. (2011) Transfer of host-derived alpha synuclein to grafted dopaminergic neurons in rat. Neurobiol. Dis. 43, 552–557.
30. Lee H. J., Khoshaghideh F., Patel S. and Lee S. J. (2004) Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway. J. Neurosci. 24, 1888–1896.
31. Lee H. J., Patel S. and Lee S. J. (2005) Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J. Neurosci. 25, 6016–6024.
32. Lee H. J., Suk J. E., Bae E. J., Lee J. H., Paik S. R. and Lee S. J. (2008a) Assembly-dependent endocytosis and clearance of extracellular alpha-synuclein. Int. J. Biochem. Cell Biol. 40, 1835–1849.
33. Lee H. J., Suk J. E., Bae E. J. and Lee S. J. (2008b) Clearance and deposition of extracellular alpha-synuclein aggregates in microglia. Biochem. Biophys. Res. Commun. 372, 423–428.
34. Lee H. J., Suk J. E., Patrick C., Bae E. J., Cho J. H., Rho S., Hwang D., Masliah E. and Lee S. J. (2010) Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J. Biol. Chem. 285, 9262–9272.
35. Li W., West N., Colla E. et al. (2005) Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc. Natl Acad. Sci. USA 102, 2162–2167.
36. Li J. Y., Englund E., Holton J. L. et al. (2008) Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat. Med. 14, 501–503.
37. Li J. Y., Englund E., Widner H., Rehncrona S., Bjorklund A., Lindvall O. and Brundin P. (2010) Characterization of Lewy body pathology in 12- and 16-year-old intrastriatal mesencephalic grafts surviving in a patient with Parkinson's disease. Mov. Disord. 25, 1091–1096.
38. Lim J. P. and Gleeson P. A. (2011) Macropinocytosis: an endocytic pathway for internalising large gulps. Immunol. Cell Biol. 89, 836–843.
39. Liu C. W., Giasson B. I., Lewis K. A., Lee V. M., Demartino G. N. and Thomas P. J. (2005) A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation: implications for pathogenesis of Parkinson disease. J. Biol. Chem. 280, 22670–22678.
40. Liu J., Zhang J. P., Shi M., Quinn T., Bradner J., Beyer R., Chen S. and Zhang J. (2009) Rab11a and HSP90 regulate recycling of extracellular alpha-synuclein. J. Neurosci. 29, 1480–1485.
41. Luk K. C., Kehm V., Carroll J., Zhang B., O'Brien P., Trojanowski J. Q. and Lee V. M. (2012a) Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338, 949–953.
42. Luk K. C., Kehm V. M., Zhang B., O'Brien P., Trojanowski J. Q. and Lee V. M. (2012b) Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice. J. Exp. Med. 209, 975–986.
43. Macia E., Ehrlich M., Massol R., Boucrot E., Brunner C. and Kirchhausen T. (2006) Dynasore, a cell-permeable inhibitor of dynamin. Dev. Cell 10, 839–850.
44. Mak S. K., McCormack A. L., Manning-Bog A. B., Cuervo A. M. and Di Monte D. A. (2010) Lysosomal degradation of alpha-synuclein in vivo. J. Biol. Chem. 285, 13621–13629.
45. Masuda-Suzukake M., Nonaka T., Hosokawa M., Oikawa T., Arai T., Akiyama H., Mann D. M. and Hasegawa M. (2013) Prion-like spreading of pathological alpha-synuclein in brain. Brain 136, 1128–1138.
46. Mougenot A. L., Nicot S., Bencsik A., Morignat E., Verchere J., Lakhdar L., Legastelois S. and Baron T. (2012) Prion-like acceleration of a synucleinopathy in a transgenic mouse model. Neurobiol. Aging 33, 2225–2228.
47. Mulcahy L. A., Pink R. C. and Carter D. R. (2014) Routes and mechanisms of extracellular vesicle uptake. J. Extracell. Vesicles 3.
48. Paxinou E., Chen Q., Weisse M., Giasson B. I., Norris E. H., Rueter S. M., Trojanowski J. Q., Lee V. M.-Y. and Ischiropoulos H. (2001) Induction of alpha-synuclein aggregation by intracellular nitrative insult. J. Neurosci. 21, 8053–8061.
49. Reyes J. F., Rey N. L., Bousset L., Melki R., Brundin P. and Angot E. (2013) Alpha-synuclein transfers from neurons to oligodendrocytes. Glia 62, 387–398.
50. Sacino A. N. and Giasson B. I. (2012) Does a prion-like mechanism play a major role in the apparent spread of alpha-synuclein pathology? Alzheimers. Res. Ther. 4, 48.
51. Sacino A. N., Brooks M., McGarvey N. H., McKinney A. B., Thomas M. A., Levites Y., Ran Y., Golde T. E. and Giasson B. I. (2013a) Induction of CNS alpha-synuclein pathology by fibrillar and non-amyloidogenic recombinant alpha-synuclein. Acta Neuropathol. Commun. 1, 38.
52. Sacino A. N., Thomas M. A., Ceballos-Diaz C., Cruz P. E., Rosario A. M., Lewis J., Giasson B. I. and Golde T. E. (2013b) Conformational templating of alpha-synuclein aggregates in neuronal-glial cultures. Mol. Neurodegener. 8, 17.
53. Sacino A. N., Brooks M., McKinney A. B., Thomas M. A., Shaw G., Golde T. E. and Giasson B. I. (2014a) Brain Injection of alpha-Synuclein Induces Multiple Proteinopathies, Gliosis, and a Neuronal Injury Marker. J. Neurosci. 34, 12368–12378.
54. Sacino A. N., Brooks M., Thomas M. A. et al. (2014b) Intramuscular injection of alpha-synuclein induces CNS alpha-synuclein pathology and a rapid-onset motor phenotype in transgenic mice. Proc. Natl Acad. Sci. USA 111, 10732–10737.
55. Sacino A. N., Brooks M., Thomas M. A. et al. (2014c) Amyloidogenic alpha-synuclein seeds do not invariably induce rapid, widespread pathology in mice. Acta Neuropathol. 127, 645–665.
56. Sung J. Y., Kim J., Paik S. R., Park J. H., Ahn Y. S. and Chung K. C. (2001) Induction of neuronal cell death by Rab5A-dependent endocytosis of alpha-synuclein. J. Biol. Chem. 276, 27441–27448.
57. Tanida I., Ueno T. and Kominami E. (2008) LC3 and autophagy. Methods Mol. Biol. 445, 77–88.
58. Tofaris G. K. (2012) Lysosome-dependent pathways as a unifying theme in Parkinson's disease. Mov. Disord. 27, 1364–1369.
59. Uchihara T. and Giasson B. I. (2015) Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies. Acta Neuropathol. 131, 49–73.
60. Vogiatzi T., Xilouri M., Vekrellis K. and Stefanis L. (2008) Wild type alpha-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells. J. Biol. Chem. 283, 23542–23556.
61. Volles M. J., Lee S.-J., Rochet J.-C., Shtilerman M. D., Ding T. T., Kessler J. C. and Lansbury P. T. (2001) Vesicle permeabilization by protofibrillar α-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 40, 7812–7819.
62. Volpicelli-Daley L. A., Luk K. C., Patel T. P., Tanik S. A., Riddle D. M., Stieber A., Meaney D. F., Trojanowski J. Q. and Lee V. M. (2011) Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 72, 57–71.
63. Wakabayashi K., Takahashi H., Takeda S., Ohama E. and Ikuta F. (1988) Parkinson's disease: the presence of Lewy bodies in Auerbach's and Meissner's plexuses. Acta Neuropathol. 76, 217–221.
64. Watts J. C., Giles K., Oehler A., Middleton L., Dexter D. T., Gentleman S. M., DeArmond S. J. and Prusiner S. B. (2013) Transmission of multiple system atrophy prions to transgenic mice. Proc. Natl Acad. Sci. USA 110, 19555–19560.
65. Waxman E. A. and Giasson B. I. (2008a) Molecular mechanisms of alpha-synuclein neurodegeneration. Biochim. Biophys. Acta 1792, 616–624.
66. Waxman E. A. and Giasson B. I. (2008b) Specificity and regulation of casein kinase-mediated phosphorylation of alpha-synuclein. J. Neuropathol. Exp. Neurol. 67, 402–416.
67. Waxman E. A. and Giasson B. I. (2010) A novel, high-efficiency cellular model of fibrillar alpha-synuclein inclusions and the examination of mutations that inhibit amyloid formation. J. Neurochem. 113, 374–388.
68. Waxman E. A. and Giasson B. I. (2011) Induction of intracellular tau aggregation is promoted by alpha-synuclein seeds and provides novel insights into the hyperphosphorylation of tau. J. Neurosci. 31, 7604–7618.
69. Waxman E. A., Duda J. E. and Giasson B. I. (2008) Characterization of antibodies that selectively detect alpha-synuclein in pathological inclusions. Acta Neuropathol. 116, 37–46.
70. Webb J. L., Ravikumar B., Atkins J., Skepper J. N. and Rubinsztein D. C. (2003) Alpha-Synuclein is degraded by both autophagy and the proteasome. J. Biol. Chem. 278, 25009–25013.
71. Wong Y. C. and Holzbaur E. L. (2015) Autophagosome dynamics in neurodegeneration at a glance. J. Cell Sci. 128, 1259–1267.
72. Yamamoto A., Tagawa Y., Yoshimori T., Moriyama Y., Masaki R. and Tashiro Y. (1998) Bafilomycin A1 prevents maturation of autophagic vacuoles by inhibiting fusion between autophagosomes and lysosomes in rat hepatoma cell line, H-4-II-E cells. Cell Struct. Funct. 23, 33–42.